Capricor CEO won’t rule out legal action against FDA after negative adcomm
After an FDA advisory committee voted 9-3 on Wednesday against recommending Capricor Therapeutics’ Duchenne muscular dystrophy cardiomyopathy drug for approval, stakeholders allege an “ulterior motive” and “biased intentions.”
Capricor CEO won’t rule out legal action against FDA after negative adcomm Read More »
